Eurofins CDMO Alphora has announced a new GMP Biologics manufacturing facility in Mississauga, Ontario, to manufacture monoclonal Antibodies (mAbs) and protein therapies for clinical and commercial applications.

The new 50 thousand square foot facility will be housed within a new 112 thousand square foot building on Eurofins CDMO Alphora’s 14 acre campus at the Sheridan Research Park, and is scheduled for completion in April 2026. Upon completion, the facility will be equipped to the 2,000 litre bioreactor scale and represents a fully integrated offering with a state-of-the-art sterile fill line with a capacity of up to 24.9 million units annually.